ReviewBiomolecules2021
Liver Regeneration and Cell Transplantation for End-Stage Liver Disease.
Review in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Subcutaneous Fat Density Is an Independent Predictor of Adverse Outcomes and Shows Early Improvement After Liver Transplantation.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Liver Xenotransplantation: From Early Primate Trials to the First-in-Human Porcine Bridging Therapies.Journal of clinical medicine · 2026Review
- Pressure enhanced dual-solid-surface ultra-rapid cooling improves post-thaw recovery in hepatocytes and precision cut liver slices.Scientific reports · 2026Article
- Effect of bone marrow mononuclear cells therapy on long-term survival of patients with liver cirrhosis: A 10-year retrospective cohort study using propensity score matching.Journal of translational internal medicine · 2025Article
- MiR-122-5p inhibits the epithelial mesenchymal transition of liver cancer cells by inducing hiPSCs to differentiate into hepatocyte-like cells.European journal of histochemistry : EJH · 2025Article
- Wharton's jelly mesenchymal stromal cells derived from preterm umbilical cord reveal a hepatogenic potential.Frontiers in cell and developmental biology · 2025Article
- Application of mesenchymal stem cells in liver fibrosis and regeneration.Liver research (Beijing, China) · 2024Review
- Farnesoid X receptor: a potential key target for maintaining liver organoid growth.Biomaterials translational · 2024Article
- Article
- Therapeutic strategies to improve liver regeneration after hepatectomy.Experimental biology and medicine (Maywood, N.J.) · 2023Review
- Magnetic Nanostructures and Stem Cells for Regenerative Medicine, Application in Liver Diseases.International journal of molecular sciences · 2023Review
- Aminodihydrophthalazinedione Sodium Transdermal Therapeutic System Specific Activity on an ExperimentalModel of Extensive Liver Resection.Life (Basel, Switzerland) · 2023Article
- Isolation, culture, and delivery considerations for the use of mesenchymal stem cells in potential therapies for acute liver failure.Frontiers in immunology · 2023Review
- The Influence of Interdisciplinary Work towards Advancing Knowledge on Human Liver Physiology.Cells · 2022Review
- Liver regeneration as treatment target for severe alcoholic hepatitis.World journal of gastroenterology · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver transplantation is the only curative option for end-stage liver disease; however, the limitations of liver transplantation require further research into other alternatives. Considering that liver regeneration is prevalent in liver injury settings, regenerative medicine is suggested as a promising therapeutic strategy for end-stage liver disease. Upon the source of regenerating hepatocytes, liver regeneration could be divided into two categories: hepatocyte-driven liver regeneration (typical regeneration) and liver progenitor cell-driven liver regeneration (alternative regeneration). Due to the massive loss of hepatocytes, the alternative regeneration plays a vital role in end-stage liver disease. Advances in knowledge of liver regeneration and tissue engineering have accelerated the progress of regenerative medicine strategies for end-stage liver disease. In this article, we generally reviewed the recent findings and current knowledge of liver regeneration, mainly regarding aspects of the histological basis of regeneration, histogenesis and mechanisms of hepatocytes' regeneration. In addition, this review provides an update on the regenerative medicine strategies for end-stage liver disease. We conclude that regenerative medicine is a promising therapeutic strategy for end-stage liver disease. However, further studies are still required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.